დასაწყისი · კატალოგი · პროფილი · ცხრილი
სკრინინგი BODY HANDBOOK
სკრინინგი · §104
Breast Cancer Screening
A mammogram every year or two from 40 to 74 lowers your chance of dying from breast cancer by roughly a fifth. That single number is the case for screening — small per appointment, real across thirty years. The hard parts come at the edges: how the test actually works, when to start, what to do if your breasts are dense or your family history is loaded, and where the honest arguments still live.
Do · Yearly Evidence Moderate თავი სკრინინგი

In the US, insurance pays from age 40. The appointment runs twenty minutes. The evidence is the strongest of any cancer screening we have — and the disagreements at the edges are real ones, about start age, frequency, and what to do with dense breasts. None of it changes the basic call: book it, then book the next one.

A mammogram is a low-dose X-ray of the breast pressed flat between two plates. Tumours and the tiny calcium specks left behind by early ductal cancer show up as bright shapes against the darker fat. The catch is that gland tissue is also bright on the same scan — so the more gland and the less fat you have, the more places a cancer can hide.

Radiologists sort breasts into four density categories from A (almost entirely fat) to D (extremely dense). About 40% of women aged 40–74 land in the two denser categories Kerlikowske 2015. In the densest, standard mammography misses something like a third of cancers Boyd 2007. That single fact is why so much of this article is about what to add on top — 3D mammography catches some of the gap, and contrast MRI catches most of the rest.

The newer machines (digital breast tomosynthesis, the "3D mammogram") take a sweep of low-dose images and reconstruct thin slices. That separates overlapping tissue and gives the radiologist a clearer view; in large population studies it finds about one extra invasive cancer per thousand screens and cuts call-backs for benign findings by around 15% compared to a flat 2D digital mammogram Friedewald 2014. Most US imaging centres have switched over; if your facility offers it and your insurer covers it, take it.

Contrast-enhanced MRI works on a different principle entirely. It uses a gadolinium dye injected into a vein; invasive cancers grow leaky, hungry blood vessels that take up the dye faster than normal tissue. MRI doesn't care how dense your breasts are — its sensitivity stays around 90% in every density category. It is the most sensitive tool we have, and the most expensive, and the most likely to call back women who don't have cancer.

What thirty years of trials actually show

Eight randomised trials run between the 1960s and early 1990s — across the US, Sweden, the UK, and Canada — invited several hundred thousand women to screening mammography and tracked them for decades. Pooled, they show roughly a 20% reduction in breast cancer deaths among the invited women, with the benefit larger and more consistent in the 50s and 60s than in the 40s Nelson 2016. One trial — the Canadian National Breast Screening Study — found no benefit, and it is the load-bearing reason careful skeptics don't consider the case fully settled Miller 2014.

The number that matters when a 50-year-old is deciding whether the appointment is worth it: across a lifetime, biennial mammography from 40 to 74 prevents roughly 1.3 breast cancer deaths per 1,000 women screened, compared with no screening at all Mandelblatt 2016. About 1 in 770. That sounds small until you remember breast cancer is common — about 1 in 8 American women will develop it. The benefit is not a transformation; it is a steady tilt in the odds, year after year, over a thirty-year exposure window.

The stage you're diagnosed at decides the rest

The mammogram doesn't cure anything — it finds. The whole game is finding early enough that finding still helps. A breast cancer caught at stage I, before it has reached lymph nodes, is typically a lumpectomy plus a few weeks of radiation, often followed by hormone-blocking pills; five-year survival is above 98%. A cancer caught at stage III usually means mastectomy, chemotherapy, hormone therapy, possibly more — and five-year survival drops to around 72%.

Without screening, about a quarter of breast cancers present at stage III or IV — found because there's a lump in the shower, or because something is already wrong somewhere else. With regular screening, that fraction roughly halves Nelson 2016. Most women who get breast cancer will survive it either way; the trade is between a late winter of radiation and a six-month detour through chemotherapy, between a routine and a year you won't get back.

When and how often

All three major US guideline bodies — the US Preventive Services Task Force, the American Cancer Society, and the American College of Radiology — now agree that average-risk women should start at 40. They disagree on frequency.

  • The USPSTF (2024) recommends biennial mammography from 40 to 74 USPSTF 2024.
  • The American Cancer Society recommends annual from 45 to 54, biennial from 55 onward, with annual from 40 as an offered option Oeffinger 2015.
  • The American College of Radiology recommends annual from 40, with no fixed upper age — stop when your remaining life expectancy is below five to seven years Mainiero 2017.

Both annual and biennial are defensible. The harm-balanced modelling that USPSTF leans on favours biennial — fewer call-backs, fewer biopsies for benign findings, fewer cancers overdiagnosed — at the cost of a small extra mortality benefit you'd get from screening every year Mandelblatt 2016. If you find the annual rhythm easier to remember, the extra benefit is real; if a two-year cadence will actually get you there, biennial is fine.

If you're higher risk than average

The base schedule above assumes average lifetime risk — somewhere around 13%. Several groups need a different one, often starting younger and adding MRI on top of mammography.

Known BRCA1 or BRCA2 mutation, or other high-penetrance variants (PALB2, TP53, CDH1). Lifetime breast cancer risk runs 50–85%. Standard high-risk regimen: annual contrast MRI starting at age 25 (BRCA, TP53) or 30 (PALB2), annual mammography added from 30, often alternated with MRI at six-month intervals so something is checking every six months Saslow 2007 Monticciolo 2018.

Chest radiation between ages 10 and 30 — typically for Hodgkin lymphoma or a bone-marrow transplant. Same high-risk regimen as the BRCA group, starting eight years after the radiation or at age 25, whichever is later. Cumulative risk by age 50 approaches that of a BRCA1 carrier.

Strong family history short of a known mutation. Two affected first-degree relatives, one relative diagnosed under 50, a male relative with breast cancer, ovarian cancer in the family, or Ashkenazi Jewish ancestry with any affected first-degree relative — any one of these is the trigger to see a genetic counsellor. If formal risk modelling (Tyrer-Cuzick, BRCAPRO) puts your lifetime risk above 20%, you qualify for the same MRI-plus-mammography regimen as known mutation carriers Saslow 2007.

Dense breasts, otherwise average risk. This is the largest subgroup the guidelines disagree on. The Dutch DENSE trial randomised 40,000 women with extremely dense (BI-RADS D) breasts to mammography alone or mammography plus MRI every two years; adding MRI cut the rate of "interval cancers" (cancers found clinically between scheduled screens, which tend to be larger and more aggressive) from 5.0 per 1,000 down to 0.8 per 1,000 Bakker 2019. The ACR recommends supplemental MRI or ultrasound for this group; the USPSTF says the evidence is not yet enough for a population recommendation. The honest take: if your density is C or D and your insurer covers it, ask about adding biennial MRI — abbreviated MRI ($300–500, ten minutes in the scanner) is making the math more reasonable than full MRI Kuhl 2014 Comstock 2020.

Biopsy-confirmed atypia or LCIS. A past biopsy that came back as atypical ductal or lobular hyperplasia, or lobular carcinoma in situ, raises lifetime risk into the 20–30% range. Same high-risk regimen of annual MRI plus mammography.

When mammography needs to wait

What most people get wrong

"Self-exam catches it instead." It doesn't. Two large randomised trials in Shanghai and Russia, more than 250,000 women combined, taught structured monthly self-exam and tracked the result for a decade: more benign biopsies, the same number of breast cancer deaths. Both the USPSTF and the American Cancer Society stopped recommending taught self-exam. Knowing your own breasts — noticing a new lump, a skin change, an inverted nipple — is sensible and not the same thing as a structured self-exam ritual, and neither replaces the scan.

"The radiation will give me cancer." A bilateral mammogram delivers about 0.4 millisieverts — roughly the natural background radiation you'd accumulate over seven weeks of just being alive. Modelling estimates one to two extra cancers caused per 100,000 women screened annually from 40 to 74, against roughly 1,300 cancer deaths prevented per 100,000. The benefit-to-harm ratio on dose alone is about a thousand to one.

"Dense breasts means something is wrong." Density is a normal anatomic finding. It is partly inherited, partly age-related (breasts get fattier and less dense after menopause), and it has nothing to do with how your breasts look or feel from the outside. It matters for two reasons: standard mammography is less sensitive in dense tissue, and women with the densest breasts have about twice the breast cancer risk of women with the least dense breasts Boyd 2007. Neither makes density itself an illness.

Where screening goes wrong

  • Skipping years. The mortality benefit accrues across decades of sustained adherence; a one-off scan in your forties barely shifts your odds. About a quarter of eligible US women report no mammogram in the last two years — the single biggest hole in real-world screening is not the protocol, it is the gap between protocol and what people actually do.
  • Not knowing your density. Through most of the 2010s, fewer than half of dense-breasted women knew it. US federal rules now require the imaging centre to put your density category in plain language on every report — read it, ask about it, decide with your doctor whether you want to add MRI.
  • Missing the genetic-counselling trigger. Primary care misses this one regularly. Any of: two affected first-degree relatives, one relative diagnosed under 50, ovarian cancer in the family, a male relative with breast cancer, Ashkenazi Jewish ancestry plus an affected first-degree relative — bring it up. A positive BRCA test changes the screening regimen completely.
  • Overdiagnosis. The hardest catch and the most honest one. Roughly 10–25% of screen-detected cancers — especially small, low-grade lesions and a fair share of ductal carcinoma in situ — would never have caused symptoms in the woman's lifetime if left alone Marmot 2013 Independent UK Panel 2012. There is no reliable way to tell prospectively which cancers those are, so every one is treated. This is the strongest argument the careful skeptics have, and it is real.
  • Stopping at the wrong moment. Continuing to screen a 75-year-old with two years of life expectancy generates more harm than benefit. Stopping a healthy fit 78-year-old gives up real benefit — the absolute incidence of breast cancer keeps rising into the 70s. The criterion is health, not a hard age.

What thirty years of doing this looks like

Most years, screening is a non-event. A reminder in your inbox, twenty minutes in a quiet imaging suite, brief compression that is uncomfortable but not painful, a normal report a week later. Three or four times across the thirty-year window you may get a call-back: an extra view, sometimes a quick ultrasound, almost always an all-clear. That is the modal experience, and it is the experience screening is designed for.

Once across that window, the appointment matters. A radiologist sees a 6-millimetre cluster of microcalcifications you couldn't feel and your partner couldn't see. The biopsy comes back as a stage I cancer — the kind that gets caught long before there's anything to feel. A lumpectomy in late winter, a few weeks of radiation through the spring, hormone-blocking pills for five years, back to your normal life by summer. People you work with don't notice anything has happened.

The version of this story without regular screening starts a year or two later, with a lump in the shower, and the surgeon's office uses different words. Most of the time both versions end with the woman still alive; the screened version uses less of her life getting there.

A few adjacent topics this entry intentionally doesn't cover. A positive BRCA test is the gateway to risk-reducing surgery (prophylactic mastectomy, oophorectomy) and to chemoprevention with tamoxifen or raloxifene — each its own decision. Lifestyle factors lower lifetime risk (less alcohol, weight control after menopause, regular exercise, breastfeeding when it fits your life) but they don't replace screening. The question of whether some early ductal carcinoma in situ should be watched rather than treated is under active trial — if your diagnosis is DCIS, ask your oncologist about the LORIS, LORD, and COMET studies. Men with BRCA2 mutations are the small group for whom male breast screening becomes relevant.

Related in the handbook
Related
  • — A strong family history is the cue to ask about BRCA testing before settling into routine mammograms.
  • — Mammograms are one line on the broader adult cancer-screening schedule — don't run them in isolation.
  • — Sits alongside cervical screening as the two routine women's cancer checks.
  • — Combined HRT slightly shifts breast-cancer risk, so staying current on mammograms is part of taking it sensibly.
  • — 'A fifth lower risk of dying' only means something against the baseline — this is how to read that number.
·
104